Trial Profile
A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 30 Jul 2018 New trial record